Forest Laboratories has entered into a definitive merger agreement to acquire Clinical Data Inc for $30 per share in cash, plus a contingent value (CVR) right worth up to $6 per share based on sales performance milestones of Clinical Data's first-of-its-kind antidepressant Viibryd (vilazodone HCl), which gained FDA approval on 24 January. The CVR is meant to allow the acquiring company to mitigate long-term risk.
Viibryd is expected to be launched in the US in the second half of this year, according to Forest's management, and is being targeted to help offset the upcoming...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?